Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The alpha-3 beta-4 (α3β4) nicotinic acetylcholine receptor is a subtype of pentameric ligand-gated ion channels primarily composed of α3 and β4 subunits. It is highly expressed in the autonomic ganglia, adrenal medulla, and specific brain regions such as the medial habenula and interpeduncular nucleus. In the peripheral nervous system, it acts as the principal ganglionic receptor mediating fast synaptic transmission, whereas in the central nervous system, it plays a critical role in modulating reward pathways and neurotransmitter release.
Due to its localization in the habenulo-interpeduncular tract, the α3β4 receptor has emerged as a key therapeutic target for substance use disorders, particularly nicotine, cocaine, and opioid addiction, where receptor inhibition has been shown to reduce drug-seeking behavior and withdrawal symptoms. Additionally, it is investigated for its involvement in overactive bladder, depression, and neuropathic pain. Pharmacological agents targeting this receptor include agonists like nicotine and cytisine, as well as non-competitive antagonists such as mecamylamine, dexmecamylamine (TC-5214), and 18-methoxycoronaridine (18-MC). However, drug development faces significant challenges, as off-target activity or systemic inhibition of ganglionic α3β4 receptors can lead to autonomic side effects, including cardiovascular fluctuations, gastrointestinal issues, and urinary retention.
Non-competitive antagonism, agonism, partial agonism, negative allosteric modulation
11 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Alpha-3 beta-4 nicotinic acetylcholine receptor (α3β4 nAChR).